New drug cocktail aims to stop liver cancer recurrence
NCT ID NCT04639180
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—can prevent liver cancer from coming back in patients at high risk of recurrence after curative surgery or ablation. About 687 participants will receive either the drug combination or active surveillance (no treatment). The main goal is to see if the combo extends the time before cancer returns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab (an immunotherapy drug) and rivoceranib (a targeted therapy drug)
What this could lead to
If successful, this combination could become a new standard treatment to delay or prevent liver cancer from coming back after surgery or ablation.
What could go wrong
This is still an experimental approach; side effects from the drugs may be serious, and it is not yet known if the benefits outweigh the risks compared to simply watching and waiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Affiliated Tumor Hospital
Nanjin, Guangzhou, China
-
Guizhou Cancer Hospital
Guiyang, Guizhou, China
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China